0.2963
price down icon0.20%   -0.0006
after-market 시간 외 거래: .28 -0.0163 -5.50%
loading
전일 마감가:
$0.2969
열려 있는:
$0.28
하루 거래량:
458.19K
Relative Volume:
0.22
시가총액:
$17.31M
수익:
$1.50M
순이익/손실:
$-64.59M
주가수익비율:
-0.1774
EPS:
-1.67
순현금흐름:
$-55.17M
1주 성능:
+5.78%
1개월 성능:
-21.61%
6개월 성능:
-89.69%
1년 성능:
-84.16%
1일 변동 폭
Value
$0.271
$0.3195
1주일 범위
Value
$0.2616
$0.3195
52주 변동 폭
Value
$0.2223
$4.79

립 테라퓨틱스 Stock (LPTX) Company Profile

Name
명칭
Leap Therapeutics Inc
Name
전화
617 252 4343
Name
주소
47 THORNDIKE STREET, CAMBRIDGE, MA
Name
직원
52
Name
트위터
@LeapTherapeutic
Name
다음 수익 날짜
2024-11-11
Name
최신 SEC 제출 서류
Name
LPTX's Discussions on Twitter

LPTX을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
LPTX
Leap Therapeutics Inc
0.2963 17.31M 1.50M -64.59M -55.17M -1.67
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
452.16 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
534.91 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
322.06 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
542.47 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.16 28.51B 3.81B -644.79M -669.77M -6.24

립 테라퓨틱스 Stock (LPTX) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-01-29 다운그레이드 H.C. Wainwright Buy → Neutral
2025-01-29 다운그레이드 Robert W. Baird Outperform → Neutral
2024-06-28 개시 Rodman & Renshaw Buy
2021-10-04 개시 Mizuho Buy
2021-06-04 재개 Robert W. Baird Outperform
2020-06-29 개시 Piper Sandler Overweight
2020-02-11 개시 Robert W. Baird Outperform
2019-11-15 다운그레이드 Raymond James Outperform → Mkt Perform
2019-09-13 재개 Raymond James Outperform
2017-03-07 개시 Ladenburg Thalmann Buy
모두보기

립 테라퓨틱스 주식(LPTX)의 최신 뉴스

pulisher
Jun 18, 2025

2025 R&D layoffs tracker hits 132,075 as Amazon CEO signals AI will cut more jobs - R&D World

Jun 18, 2025
pulisher
Jun 16, 2025

Layoff Tracker: Gilead Cuts 36 Employees in California - BioSpace

Jun 16, 2025
pulisher
Jun 12, 2025

Fierce Biotech Layoff Tracker 2025: ADC Tx lets go of 30% of workers; Vertex sheds 125 staffers - Fierce Biotech

Jun 12, 2025
pulisher
Jun 10, 2025

Ligachem inks two mystery ADC deals with CSPC subsidiary Novarock - BioWorld MedTech

Jun 10, 2025
pulisher
Jun 09, 2025

HER2+ Gastric Cancer (including GEJ) Market to Increase at a Remarkable Growth Rate of 13% During the Study Period (2020-2034) | DelveInsight - The Malaysian Reserve

Jun 09, 2025
pulisher
Jun 09, 2025

Prostate Cancer Treatment Market Size in the 7MM was ~USD 12,300 million in 2023 and is expected to show positive growth by 2034, estimates DelveInsight - Barchart.com

Jun 09, 2025
pulisher
Jun 08, 2025

Jane Street Group LLC Decreases Holdings in Dakota Gold Corp. (NYSE:DC) - Defense World

Jun 08, 2025
pulisher
Jun 08, 2025

Jane Street Group LLC Purchases New Position in Leap Therapeutics, Inc. (NASDAQ:LPTX) - Defense World

Jun 08, 2025
pulisher
May 28, 2025

Leap Therapeutics Reports Increased Q1 Losses - TipRanks

May 28, 2025
pulisher
May 21, 2025

Metastatic Colorectal Cancer Pipeline Appears Robust With 150+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - Barchart.com

May 21, 2025
pulisher
May 21, 2025

Finance Watch: Prime, Kyverna, Allogene And More Announce Job Cuts - insights.citeline.com

May 21, 2025
pulisher
May 20, 2025

CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Shares Leap 225% Yet They're Still Not Telling The Full Story - simplywall.st

May 20, 2025
pulisher
May 17, 2025

HC Wainwright Issues Optimistic Outlook for LPTX Earnings - Defense World

May 17, 2025
pulisher
May 13, 2025

Metastatic Colorectal Cancer Clinical Trial Pipeline Accelerates as 150+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - GlobeNewswire

May 13, 2025
pulisher
May 13, 2025

Metastatic Colorectal Cancer Clinical Trial Pipeline Accelerates as 150+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - GlobeNewswire Inc.

May 13, 2025
pulisher
May 13, 2025

Cash-strapped Cambridge cancer biotech cuts 50% of its staff - NBC Boston

May 13, 2025
pulisher
May 13, 2025

Cash-strapped Cambridge cancer biotech halves workforce - The Business Journals

May 13, 2025
pulisher
May 13, 2025

Leap halves head count, narrows lead cancer drug's focus amid 'difficult market environment' - Fierce Biotech

May 13, 2025
pulisher
May 13, 2025

Leap Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 13, 2025
pulisher
May 13, 2025

Leap Therapeutics Q1 Net Income USD -15.435 Million - marketscreener.com

May 13, 2025
pulisher
May 13, 2025

Leap Therapeutics Reports First Quarter 2025 Financial Results | - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Leap Therapeutics Reports First Quarter 2025 Financial Results - Citizen Tribune

May 13, 2025
pulisher
May 13, 2025

Leap TherapeuticsAnnounces 50% Workforce Reduction In Strategic RestructuringSEC Filing - marketscreener.com

May 13, 2025
pulisher
May 13, 2025

Leap Therapeutics, Inc. (LPTX) Q1 Loss Beats Estimates - Nasdaq

May 13, 2025
pulisher
May 13, 2025

LEAP THERAPEUTICS, INC. SEC 10-Q Report - TradingView

May 13, 2025
pulisher
May 13, 2025

Leap Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com

May 13, 2025
pulisher
May 12, 2025

Purple Biotech Appoints Shai Lankry as Chief Financial Officer - The Manila Times

May 12, 2025
pulisher
May 10, 2025

Leap Therapeutics (LPTX) Expected to Announce Quarterly Earnings on Monday - Defense World

May 10, 2025
pulisher
May 09, 2025

Leap Therapeutics Inc expected to post a loss of 38 cents a shareEarnings Preview - TradingView

May 09, 2025
pulisher
May 07, 2025

Closing Bell Recap: Leap Therapeutics Inc (LPTX) Ends at 0.34, Reflecting a -12.39 Downturn - DWinneX

May 07, 2025
pulisher
May 01, 2025

LPTX’s Market Whiplash: -85.46% YTD Decline, 37.04% Rise in 30 Days - investchronicle.com

May 01, 2025
pulisher
Apr 30, 2025

75,800 Shares in Leap Therapeutics, Inc. (NASDAQ:LPTX) Acquired by LPL Financial LLC - Defense World

Apr 30, 2025
pulisher
Apr 30, 2025

Enovix Corporation (NASDAQ: ENVX)’s Potential for Significant Price Increase in the Near Future - Marketing Sentinel

Apr 30, 2025
pulisher
Apr 29, 2025

Quarterly Snapshot: Quick and Current Ratios for Leap Therapeutics Inc (LPTX) - DWinneX

Apr 29, 2025
pulisher
Apr 25, 2025

Leap Therapeutics to Present Preclinical Data of FL-501, a Novel - GuruFocus

Apr 25, 2025
pulisher
Apr 25, 2025

Novel Cancer Cachexia Drug FL-501 Shows 3X Better Half-Life in Preclinical Data | LPTX Stock News - Stock Titan

Apr 25, 2025
pulisher
Apr 25, 2025

Leap Therapeutics to Present Preclinical Data of FL-501, a Novel GDF-15 Neutralizing Antibody, at the AACR 2025 Annual Meeting - PR Newswire

Apr 25, 2025
pulisher
Apr 23, 2025

Metastatic Colorectal Cancer Market Poised for Expansion Across the 7MM During the Forecast Period (2025-2034) as Breakthrough Therapies Gain Traction | DelveInsight - PR Newswire

Apr 23, 2025
pulisher
Apr 15, 2025

Leap Therapeutics to Host Virtual KOL Event to Discuss Sirexatam - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

Leap Therapeutics to Host Virtual KOL Event to Discuss Sirexatamab (DKN-01) in Second-line Patients with Advanced Microsatellite Stable Colorectal Cancer | LPTX Stock News - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

Leading Oncologist Reveals Game-Changing Phase 2 Results for Advanced Colorectal Cancer Treatment - Stock Titan

Apr 15, 2025
pulisher
Apr 15, 2025

Leap Therapeutics to Host Virtual KOL Event to Discuss Sirexatamab (DKN-01) in Second-line Patients with Advanced Microsatellite Stable Colorectal Cancer - PR Newswire

Apr 15, 2025
pulisher
Apr 05, 2025

Leap Therapeutics stock hits 52-week low at $0.28 amid downturn - Investing.com Canada

Apr 05, 2025
pulisher
Apr 04, 2025

Leap Therapeutics stock hits 52-week low at $0.28 amid downturn By Investing.com - Investing.com South Africa

Apr 04, 2025
pulisher
Apr 03, 2025

BlossomHill Therapeutics to Present the Design and Discovery of BH-30643, the Company’s OMNI-EGFR™ Inhibitor, at the 2025 AACR Annual Meeting - Business Wire

Apr 03, 2025
pulisher
Mar 31, 2025

HC Wainwright Expects Reduced Earnings for Leap Therapeutics - Defense World

Mar 31, 2025
pulisher
Mar 29, 2025

Leap Therapeutics (NASDAQ:LPTX) Earns Neutral Rating from HC Wainwright - The AM Reporter

Mar 29, 2025
pulisher
Mar 29, 2025

HC Wainwright Reiterates Neutral Rating for Leap Therapeutics (NASDAQ:LPTX) - Defense World

Mar 29, 2025
pulisher
Mar 28, 2025

H.C. Wainwright maintains neutral on Leap Therapeutics stock By Investing.com - Investing.com Canada

Mar 28, 2025
pulisher
Mar 27, 2025

12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga

Mar 27, 2025

립 테라퓨틱스 (LPTX) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$20.74
price up icon 0.39%
$35.88
price down icon 0.42%
$21.20
price down icon 0.38%
$97.62
price down icon 3.00%
$107.51
price up icon 0.98%
biotechnology ONC
$245.16
price up icon 1.28%
자본화:     |  볼륨(24시간):